ElectroCore (ECOR) said Friday it completed its merger with NeuroMetrix (NURO), gaining ownership of the Quell Fibromyalgia Solution platform.
As part of the merger agreement, NeuroMetrix shareholders received $4.49 in cash per share along with a contingent value right linked to future sales milestones of the Quell business and potential proceeds from the sale of NeuroMetrix's DPNCheck business, the company said.
Following the merger, NeuroMetrix became an indirect wholly owned subsidiary of electroCore, and its shares were delisted from Nasdaq on Friday.
Shares of electroCore were up 11% in recent trading.
Price: 8.40, Change: +0.83, Percent Change: +10.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。